A newly detected designer opioid has been found in four Toronto fentanyl samples, adding another unknown to an unregulated drug supply already marked by mixtures of potent opioids and sedatives, according to reporting by The Canadian Press published by CityNews.

Toronto’s Drug Checking Service first detected the substance in October. It is the sixth new substance the service has found in the city’s fentanyl supply this year, and its strength and effects remain unknown.

Karen McDonald, executive director of the service, which operates out of St. Michael’s Hospital, said the drug is so new that it does not yet have a generic name. Testing cannot currently distinguish between two closely related compounds: N’-Phenethyl-5-chloro nor-orphine and N’-Phenethyl-6-chloro nor-orphine. The substance has also been detected in Vancouver.

It belongs to the orphine class of opioids. Late last year, the Toronto service began finding another member of that class, cychlorphine, believed to be about 10 times stronger than fentanyl. That estimate does not establish the potency of the newly detected substance, for which little research is available.

“This is a really good example of what we’re dealing with, with the unregulated fentanyl supply,” McDonald said. “It is just evolving, and the substances that are presenting are incredibly novel.”

Cristiana Stefan, a laboratory director and clinical biochemist at the Centre for Addiction and Mental Health, said she is concerned about how the new opioid may interact with other drugs. Her team spent weeks working to identify the substance in October’s samples.

Those concerns arise against a backdrop of extensive mixing. In the drug checking service’s latest report, 96 per cent of fentanyl samples contained at least one non-opioid drug, usually a veterinary tranquillizer or a benzodiazepine. During the same reporting period, 83 per cent contained multiple high-potency opioids.

More than a quarter contained a combination of a high-potency opioid, a veterinary tranquillizer and a benzodiazepine.

National figures cited in the reporting also show a growing role for multiple substances in overdose deaths. Between 2018 and 2023, the share of opioid or stimulant overdose deaths involving three or more substances rose from 20 per cent to 42 per cent, according to the Public Health Agency of Canada.

Source: CityNews — reporting by The Canadian Press on Toronto’s newly detected designer opioid.

Sources